{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T18:47:01Z","timestamp":1773341221257,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG - 68647618"],"award-info":[{"award-number":["DFG - 68647618"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>One of the most studied, and preclinically as well as clinically applied gastrin-releasing peptide receptor (GRPR) ligands represents the antagonist RM2 (DOTA-Pip<jats:sup>5<\/jats:sup>-D-Phe<jats:sup>6<\/jats:sup>-Gln<jats:sup>7<\/jats:sup>-Trp<jats:sup>8<\/jats:sup>-Ala<jats:sup>9<\/jats:sup>-Val<jats:sup>10<\/jats:sup>-Gly<jats:sup>11<\/jats:sup>-His<jats:sup>12<\/jats:sup>-Sta<jats:sup>13<\/jats:sup>-Leu<jats:sup>14<\/jats:sup>-NH<jats:sub>2<\/jats:sub>). As an improved in vivo stability was observed for a RM2 analog comprising the unnatural amino acid <jats:italic>\u03b1<\/jats:italic>-methyl-L-tryptophan instead of L-Trp, we aimed to elucidate the impact of other unnatural amino acids (homoserine [Hse], <jats:italic>\u03b2<\/jats:italic>-(3-benzothienyl)alanine [Bta]) at the metabolically less stable Gln-Trp site. Furthermore, we conjugated either DOTA, NOTA or NODAGA to the RM2 peptide and its modified derivatives, and evaluated each analog preclinically using <jats:sup>68<\/jats:sup>Ga and <jats:sup>64<\/jats:sup>Cu, as well as <jats:sup>177<\/jats:sup>Lu (only DOTA-comprising compounds).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>GRPR affinity and lipophilicity of RM2 derivatives were in a range of 1.2\u20138.4\u00a0nM and\u2009\u2212\u20092.9 to\u2009\u2212\u20091.1 (<jats:sup>nat\/68<\/jats:sup>Ga-labeled), 1.7\u201333.0\u00a0nM and\u2009\u2212\u20092.4 to\u2009\u2212\u20091.6 (<jats:sup>nat\/64<\/jats:sup>Cu-labeled), as well as 3.0\u201319.7\u00a0nM and\u2009\u2212\u20093.2 to\u2009\u2212\u20091.8 (<jats:sup>nat\/177<\/jats:sup>Lu-labeled), respectively. Both, [<jats:sup>177<\/jats:sup>Lu]Lu-[Hse<jats:sup>7<\/jats:sup>]RM2 and [<jats:sup>177<\/jats:sup>Lu]Lu-[Bta<jats:sup>8<\/jats:sup>]RM2 revealed distinctly lower in vivo stability (&lt;\u200920% intact at 15\u00a0min post-injection) than [<jats:sup>177<\/jats:sup>Lu]Lu-[<jats:italic>\u03b1<\/jats:italic>-Me-Trp<jats:sup>8<\/jats:sup>]RM2 (=\u2009[<jats:sup>177<\/jats:sup>Lu]Lu-AMTG) and [<jats:sup>177<\/jats:sup>Lu]Lu-RM2 (&gt;\u200930% intact at 30\u00a0min post-injection). Both [<jats:sup>68<\/jats:sup>Ga]Ga-RM2 and [<jats:sup>68<\/jats:sup>Ga]Ga-AMTG exhibited high tumor (~\u200915 percentage injected dose per gram, %ID\/g) and pancreas uptake (&gt;\u200925%ID\/g), whereas [<jats:sup>68<\/jats:sup>Ga]Ga-[Hse<jats:sup>7<\/jats:sup>]RM2 and [<jats:sup>68<\/jats:sup>Ga]Ga-[Bta<jats:sup>8<\/jats:sup>]RM2 revealed lower tumor (~\u20097.5%ID\/g) but also substantially lower pancreas uptake (&lt;\u20098%ID\/g) at 1\u00a0h post-injection. At 24\u00a0h post-injection (p.i.), [<jats:sup>177<\/jats:sup>Lu]Lu-RM2 and [<jats:sup>177<\/jats:sup>Lu]Lu-AMTG exhibited high (&gt;\u20098% ID\/g) while [<jats:sup>177<\/jats:sup>Lu]Lu-[Hse<jats:sup>7<\/jats:sup>]RM2 and [<jats:sup>177<\/jats:sup>Lu]Lu-[Bta<jats:sup>8<\/jats:sup>]RM2 displayed low tumor retention (~\u20092%ID\/g). All compounds showed low activity levels in the pancreas at 24\u00a0h post-injection (&lt;\u20091%ID\/g).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Substitution of the Gln-Trp site in RM2 by artificial amino acids had a distinct impact on overall pharmacokinetics. While Hse (instead of Gln) and Bta (instead of Trp) led to a decreased, <jats:italic>\u03b1<\/jats:italic>-Me-Trp (instead of Trp) led to an increased in vivo stability, which resulted in improved pharmacokinetics over time in case of the latter. However, at 1\u00a0h post-injection both [<jats:sup>68<\/jats:sup>Ga]Ga-[Hse<jats:sup>7<\/jats:sup>]RM2 and [<jats:sup>68<\/jats:sup>Ga]Ga-[Bta<jats:sup>8<\/jats:sup>]RM2 displayed slightly higher tumor-to-pancreas and tumor-to-intestine ratios, rendering homoserine and <jats:italic>\u03b2<\/jats:italic>-(3-benzothienyl)alanine potential options for the modification of GRPR ligands with regard to imaging properties.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13550-025-01241-7","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T16:00:35Z","timestamp":1756742435000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Studies on the impact of modifications at the Gln-Trp site in RM2-based GRPR ligands"],"prefix":"10.1186","volume":"15","author":[{"given":"Sebastian","family":"Fischer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Koller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Dominelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roswitha","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-J\u00fcrgen","family":"Wester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7412-0297","authenticated-orcid":false,"given":"Thomas","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"issue":"1","key":"1241_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-024-02041-6","volume":"10","author":"S Zhang","year":"2025","unstructured":"Zhang S, Wang X, Gao X, Chen X, Li L, Li G, et al. Radiopharmaceuticals and their applications in medicine. Signal Transduct Target Ther. 2025;10(1):1.","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"1241_CR2","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1021\/acs.molpharmaceut.4c00066","volume":"21","author":"Y Zou","year":"2024","unstructured":"Zou Y, Huang M, Hu M, Wang H, Chen W, Tian R. Radiopharmaceuticals targeting gastrin-releasing peptide receptor for diagnosis and therapy of prostate cancer. Mol Pharm. 2024;21(9):4199\u2013216.","journal-title":"Mol Pharm"},{"issue":"5","key":"1241_CR3","first-page":"1152","volume":"59","author":"R Markwalder","year":"1999","unstructured":"Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate relation to neoplastic transformation. Cancer Res. 1999;59(5):1152\u20139.","journal-title":"Cancer Res"},{"issue":"12","key":"1241_CR4","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1002\/ijc.25000","volume":"126","author":"RP Schroeder","year":"2010","unstructured":"Schroeder RP, de Visser M, van Weerden WM, de Ridder CM, Reneman S, Melis M, et al. Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts. Int J Cancer. 2010;126(12):2826\u201334.","journal-title":"Int J Cancer"},{"issue":"1","key":"1241_CR5","doi-asserted-by":"publisher","first-page":"2320301","DOI":"10.1080\/07853890.2024.2320301","volume":"56","author":"H Zhang","year":"2024","unstructured":"Zhang H, Qi L, Cai Y, Gao X. Gastrin-releasing peptide receptor (GRPR) as a novel biomarker and therapeutic target in prostate cancer. Ann Med. 2024;56(1):2320301.","journal-title":"Ann Med"},{"issue":"9","key":"1241_CR6","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2967\/jnumed.116.188011","volume":"58","author":"C Morgat","year":"2017","unstructured":"Morgat C, MacGrogan G, Brouste V, Velasco V, Sevenet N, Bonnefoi H, et al. Expression of gastrin-releasing peptide receptor in breast cancer and its association with pathologic, biologic, and clinical parameters: a study of 1,432 primary tumors. J Nucl Med. 2017;58(9):1401\u20137.","journal-title":"J Nucl Med"},{"issue":"11","key":"1241_CR7","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.3390\/biomedicines10112899","volume":"10","author":"L Gruber","year":"2022","unstructured":"Gruber L, Decristoforo C, Uprimny C, Hohenberger P, Schoenberg SO, Orlandi F, Mariani MF, Manzl C, Kasseroler MT, Tilg H, Zelger B, Jaschke WR, Virgolini IJ. Imaging properties and tumor targeting of 68Ga-NeoBOMB1, a gastrin-releasing peptide receptor antagonist, in GIST patients. Biomedicines. 2022;10(11):2899. https:\/\/doi.org\/10.3390\/biomedicines10112899.","journal-title":"Biomedicines"},{"issue":"2","key":"1241_CR8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2967\/jnumed.124.267810","volume":"66","author":"R Wang","year":"2024","unstructured":"Wang R, Kang W, Liu Z, Zheng Y, Sui H, Li L, Wang J, Xiang J, Peng X, Chen X, Zhu Z, Zhang J. Head-to-head comparison of [68Ga]Ga-NOTA-RM26 and [18F]FDG PET\/CT in patients with gastrointestinal stromal tumors: a prospective study. J Nuclear Med. 2024;66(2):201\u20136. https:\/\/doi.org\/10.2967\/jnumed.124.267810.","journal-title":"J Nuclear Med"},{"issue":"6","key":"1241_CR9","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1007\/s11307-014-0754-z","volume":"16","author":"SJ Mather","year":"2014","unstructured":"Mather SJ, Nock BA, Maina T, Gibson V, Ellison D, Murray I, et al. GRP receptor imaging of prostate cancer using [99mTc]Demobesin 4: a first-in-man study. Mol Imag Biol. 2014;16(6):888\u201395.","journal-title":"Mol Imag Biol"},{"issue":"6","key":"1241_CR10","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2967\/jnumed.112.114082","volume":"54","author":"A Roivainen","year":"2013","unstructured":"Roivainen A, Kahkonen E, Luoto P, Borkowski S, Hofmann B, Jambor I, et al. Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86\u20137548 in healthy men. J Nucl Med. 2013;54(6):867\u201372.","journal-title":"J Nucl Med"},{"issue":"6","key":"1241_CR11","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s11307-018-1185-z","volume":"20","author":"IL Bakker","year":"2018","unstructured":"Bakker IL, van Tiel ST, Haeck J, Doeswijk GN, de Blois E, Segbers M, et al. In Vivo Stabilized SB3, an attractive GRPR antagonist, for pre- and intra-operative imaging for prostate cancer. Mol Imaging Biol. 2018;20(6):973\u201383.","journal-title":"Mol Imaging Biol"},{"issue":"63","key":"1241_CR12","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.2967\/jnumed.121.263323","volume":"63","author":"T Guenther","year":"2022","unstructured":"Guenther T, Deiser S, Felber V, Beck R, Wester HJ. Substitution of L-tryptophan by a-methyl-L-tryptophan in 177Lu-RM2 results in 177Lu-AMTG, a high-affinity gastrin-releasing peptide receptor ligand with improved In vivo stability. J Nucl Med. 2022;63(63):1364\u201370.","journal-title":"J Nucl Med"},{"key":"1241_CR13","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.123.266537","volume":"65","author":"T G\u00fcnther","year":"2024","unstructured":"G\u00fcnther T, Felber V, Holzleitner N, Joksch M, Suhrbier T, Schwarzenb\u00f6ck S, et al. In vivo stability of the GRPR antagonist [177Lu]Lu-AMTG in prostate cancer patients: a first step towards improved radioligand therapy. J Nucl Med. 2024;65: 242235.","journal-title":"J Nucl Med"},{"key":"1241_CR14","volume":"65","author":"J Kurth","year":"2024","unstructured":"Kurth J, Heuschkel M, Felber V, Joksch M, Koller L, Wester H-J, et al. GRPr antagonist [177Lu]Lu-AMTG for treatment of castration resistant prostate cancer: first in-human biodistribution and dosimetry. J Nucl Med. 2024;65: 242300.","journal-title":"J Nucl Med"},{"key":"1241_CR15","doi-asserted-by":"publisher","first-page":"10662","DOI":"10.1073\/pnas.88.23.10662","volume":"88","author":"MA Shipp","year":"1991","unstructured":"Shipp MA, Tarr GE, Chen CY, Switzer SN, Hersh LB, Stein H, et al. CD10neutral endopeptidase 2411 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc Natl Acad Sci. 1991;88:10662\u20136.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"1241_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2967\/jnumed.113.129411","volume":"55","author":"BA Nock","year":"2014","unstructured":"Nock BA, Maina T, Krenning EP, de Jong M. To serve and protect: enzyme inhibitors as radiopeptide escorts promote tumor targeting. J Nucl Med. 2014;55(1):121\u20137.","journal-title":"J Nucl Med"},{"issue":"5","key":"1241_CR17","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/ph17050621","volume":"17","author":"L Wang","year":"2024","unstructured":"Wang L, Chen C-C, Zhang Z, Kuo H-T, Zhang C, Colpo N, Merkens H, B\u00e9nard F, Lin K-S. Synthesis and evaluation of Novel 68Ga-labeled [D-Phe6,Leu13\u03c8Thz14]bombesin(6-14) Analogs for cancer imaging with positron emission tomography. Pharmaceuticals. 2024;17(5):621. https:\/\/doi.org\/10.3390\/ph17050621.","journal-title":"Pharmaceuticals"},{"issue":"1","key":"1241_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s41181-024-00241-7","volume":"9","author":"L Wang","year":"2024","unstructured":"Wang L, Kuo HT, Zhang Z, Zhang C, Chen CC, Chapple D, et al. Unnatural amino acid substitutions to improve in vivo stability and tumor uptake of (68)Ga-labeled GRPR-targeted TacBOMB2 derivatives for cancer imaging with positron emission tomography. EJNMMI Radiopharm Chem. 2024;9(1):8.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"1","key":"1241_CR19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40658-022-00487-7","volume":"9","author":"A Braune","year":"2022","unstructured":"Braune A, Oehme L, Freudenberg R, Hofheinz F, van den Hoff J, Kotzerke J, et al. Comparison of image quality and spatial resolution between (18)F, (68)Ga, and (64)Cu phantom measurements using a digital Biograph Vision PET\/CT. EJNMMI Phys. 2022;9(1):58.","journal-title":"EJNMMI Phys"},{"issue":"13","key":"1241_CR20","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1007\/s00259-021-05426-9","volume":"48","author":"T Liu","year":"2021","unstructured":"Liu T, Liu C, Zhang Z, Zhang N, Guo X, Xia L, et al. (64)Cu-PSMA-BCH: a new radiotracer for delayed PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48(13):4508\u201316.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1241_CR21","doi-asserted-by":"publisher","first-page":"451","DOI":"10.2967\/jnumed.116.180430","volume":"58","author":"CB Johnbeck","year":"2017","unstructured":"Johnbeck CB, Knigge U, Loft A, Berthelsen AK, Mortensen J, Oturai P, et al. Head-to-head comparison of (64)Cu-DOTATATE and (68)Ga-DOTATOC PET\/CT: a prospective study of 59 patients with neuroendocrine tumors. J Nucl Med. 2017;58(3):451\u20137.","journal-title":"J Nucl Med"},{"issue":"6","key":"1241_CR22","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1021\/jm030383m","volume":"47","author":"CA Boswell","year":"2004","unstructured":"Boswell CA, Sun X, Niu W, Weisman GR, Wong EH, Rheingold AL, et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem. 2004;47(6):1465\u201374.","journal-title":"J Med Chem"},{"issue":"4","key":"1241_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195802","volume":"13","author":"SN Rylova","year":"2018","unstructured":"Rylova SN, Stoykow C, Del Pozzo L, Abiraj K, Tamma ML, Kiefer Y, et al. The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model. PLoS ONE. 2018;13(4): e0195802.","journal-title":"PLoS ONE"},{"issue":"10","key":"1241_CR24","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.2967\/jnumed.123.265771","volume":"64","author":"L Koller","year":"2023","unstructured":"Koller L, Joksch M, Schwarzenb\u00f6ck S, Kurth J, Heuschkel M, Holzleitner N, et al. Preclinical comparison of the (64)Cu- and (68)Ga-Labeled GRPR-targeted compounds RM2 and AMTG, as Well as First-in-Humans [(68)Ga]Ga-AMTG PET\/CT. J Nucl Med. 2023;64(10):1654\u20139.","journal-title":"J Nucl Med"},{"issue":"5","key":"1241_CR25","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.nucmedbio.2014.12.009","volume":"42","author":"Z Varasteh","year":"2015","unstructured":"Varasteh Z, Mitran B, Rosenstrom U, Velikyan I, Rosestedt M, Lindeberg G, et al. The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26. Nucl Med Biol. 2015;42(5):446\u201354.","journal-title":"Nucl Med Biol"},{"issue":"5","key":"1241_CR26","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.3892\/ijo.2016.3429","volume":"48","author":"B Mitran","year":"2016","unstructured":"Mitran B, Varasteh Z, Selvaraju RK, Lindeberg G, Sorensen J, Larhed M, et al. Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26. Int J Oncol. 2016;48(5):2124\u201334.","journal-title":"Int J Oncol"},{"issue":"4","key":"1241_CR27","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/0006-291X(78)91322-0","volume":"80","author":"PJ Fraker","year":"1978","unstructured":"Fraker PJ, Speck JC Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun. 1978;80(4):849\u201357.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1241_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13550-014-0063-1","volume":"4","author":"M Weineisen","year":"2014","unstructured":"Weineisen M, Simecek J, Schottelius M, Schwaiger M, Wester HJ. Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res. 2014;4(1):63.","journal-title":"EJNMMI Res"},{"issue":"6","key":"1241_CR29","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1021\/bc9000189","volume":"20","author":"KE Linder","year":"2009","unstructured":"Linder KE, Metcalfe E, Arunachalam T, Chen J, Eaton SM, Feng W, et al. In Vitro and in Vivo Metabolism of Lu-AMBA and the synthesis and characterization of its metabolites. Bioconjugate Chem. 2009;20(6):1171\u20138.","journal-title":"Bioconjugate Chem"},{"key":"1241_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.nucmedbio.2016.11.004","volume":"45","author":"I Popp","year":"2017","unstructured":"Popp I, Del Pozzo L, Waser B, Reubi JC, Meyer PT, Maecke HR, et al. Approaches to improve metabolic stability of a statine-based GRP receptor antagonist. Nucl Med Biol. 2017;45:22\u20139.","journal-title":"Nucl Med Biol"},{"issue":"1","key":"1241_CR31","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00259-010-1596-9","volume":"38","author":"R Mansi","year":"2011","unstructured":"Mansi R, Wang X, Forrer F, Waser B, Cescato R, Graham K, et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging. 2011;38(1):97\u2013107.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1241_CR32","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2967\/jnumed.123.266233","volume":"65","author":"N Holzleitner","year":"2024","unstructured":"Holzleitner N, Cwojdzinski T, Beck R, Urtz-Urban N, Hillhouse CC, Grundler PV, et al. Preclinical evaluation of gastrin-releasing peptide receptor antagonists labeled with (161)Tb and (177)Lu: a comparative study. J Nucl Med. 2024;65(3):481\u20134.","journal-title":"J Nucl Med"},{"issue":"4","key":"1241_CR33","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.3390\/molecules28041977","volume":"28","author":"L Wang","year":"2023","unstructured":"Wang L, Bratanovic IJ, Zhang Z, Kuo H-T, Merkens H, Zeisler J, Zhang C, Tan R, B\u00e9nard F, Lin K-S. 68Ga-labeled [Thz14]Bombesin(7\u201314) Analogs: promising GRPR-targeting agonist pet tracers with low pancreas uptake. Molecules. 2023;28(4):1977. https:\/\/doi.org\/10.3390\/molecules28041977.","journal-title":"Molecules"},{"issue":"12","key":"1241_CR34","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.3390\/molecules27123777","volume":"27","author":"L Wang","year":"2022","unstructured":"Wang L, Zhang Z, Merkens H, Zeisler J, Zhang C, Roxin A, Tan R, B\u00e9nard F, Lin K-S. 68Ga-labeled [Leu13\u03c8Thz14]Bombesin(7\u201314) derivatives: promising GRPR-targeting PET tracers with low pancreas uptake. Molecules. 2022;27(12):3777. https:\/\/doi.org\/10.3390\/molecules27123777.","journal-title":"Molecules"},{"issue":"1","key":"1241_CR35","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1021\/acsomega.8b03293","volume":"4","author":"J Lau","year":"2019","unstructured":"Lau J, Rousseau E, Zhang Z, Uribe CF, Kuo HT, Zeisler J, et al. Positron emission tomography imaging of the gastrin-releasing peptide receptor with a novel bombesin analogue. ACS Omega. 2019;4(1):1470\u20138.","journal-title":"ACS Omega"},{"issue":"3","key":"1241_CR36","doi-asserted-by":"publisher","first-page":"424","DOI":"10.2967\/jnumed.120.257758","volume":"63","author":"IJ Bratanovic","year":"2022","unstructured":"Bratanovic IJ, Zhang C, Zhang Z, Kuo HT, Colpo N, Zeisler J, et al. A radiotracer for molecular imaging and therapy of gastrin-releasing peptide receptor-positive prostate cancer. J Nucl Med. 2022;63(3):424\u201330.","journal-title":"J Nucl Med"},{"issue":"9","key":"1241_CR37","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.3390\/ph15091133","volume":"15","author":"T G\u00fcnther","year":"2022","unstructured":"G\u00fcnther T, Konrad M, Stopper L, Kunert J-P, Fischer S, Beck R, Casini A, Wester H-J. Optimization of the pharmacokinetic profile of [99mTc]Tc-N4-bombesin derivatives by modification of the pharmacophoric Gln-Trp sequence. Pharmaceuticals. 2022;15(9):1133. https:\/\/doi.org\/10.3390\/ph15091133.","journal-title":"Pharmaceuticals"},{"issue":"1","key":"1241_CR38","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13550-024-01105-6","volume":"14","author":"A Rinscheid","year":"2024","unstructured":"Rinscheid A, Gable A, Wienand G, Dierks A, Kircher M, Gunther T, et al. Biodistribution and radiation dosimetry of [(99m)Tc]Tc-N4-BTG in patients with biochemical recurrence of prostate cancer. EJNMMI Res. 2024;14(1):42.","journal-title":"EJNMMI Res"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01241-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-025-01241-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01241-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T01:54:47Z","timestamp":1757469287000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-025-01241-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1241"],"URL":"https:\/\/doi.org\/10.1186\/s13550-025-01241-7","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"10 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Nothing to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A patent application on modified GRPR-targeted antagonists with H.-J.W. and T.G. as co-inventors has been filed. H.-J.W. is founder and shareholder of Scintomics GmbH, Munich, Germany. No other potential conflicts of interest relevant to this article exist.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"114"}}